|
| Exchange Disseminated Time 22/04/2017 18:10:11 | The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd with respect to news article appearing on ET NOW on April 21, 2017 titled "FDA issues 11 observations for Dadra unit."
Sun Pharmaceutical Industries Ltd response is below;
"Please note that the Company's Dadra facility underwent an inspection by US FDA recently. This inspection was completed on April 13, 2017. A Form-483 observation letter was issued by the US FDA post the inspection, listing 11 observations. We are currently in the process of responding to the said letter to the US FDA within the stipulated timeline of 15 days.
Please further note that Sun Pharma and its subsidiaries have many facilities which supply products to the US market. These facilities undergo periodic routine inspection by the US FDA in normal course of business. As indicated above, we are in the process of responding to the US FDA for the Form-483 observation letter issued for the Dadra facility. If there are any material developments related to this inspection, we will promptly inform the stock exchanges.
We hereby confirm that Company is not aware of any information that has not been announced to the Exchanges under Regulation 30 of Listing Regulations." |
|
|